Ex­clu­sive: Men­tal health start­up Head­light rais­es $18M in a round backed by Pill­Pack co­founder TJ Park­er

Last year
Startups
Health Tech

Ex­clu­sive: Pri­ma­ry care ri­vals Marathon Health and Ever­side Health merge

Last year
Health Tech

Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Last year
Financing
Startups

Re­genxbio to seek ac­cel­er­at­ed ap­proval of Hunter syn­drome gene ther­a­py us­ing bio­mark­er da­ta

Last year
R&D
Cell/Gene Tx

An eye-drop ver­sion of Krys­tal Biotech's skin gene ther­a­py helped re­store vi­sion of boy with rare dis­ease

Last year
R&D
Cell/Gene Tx

House com­mit­tee plans hear­ing on Chi­nese biotech com­pe­ti­tion as ten­sions mount

Last year
China
Pharma

New hear­ing, same blame game: Phar­ma, PBMs trade ac­cu­sa­tions ahead of Sen­ate ses­sion

Last year
Pharma

Genen­tech is Broad­way bound with lat­est cam­paign to raise spinal mus­cu­lar at­ro­phy aware­ness

Last year
Pharma
Marketing

EMA seeks to ease the reg­u­la­to­ry bur­den on biosim­i­lar de­vel­op­ers, fol­low­ing push by FDA

Last year
FDA+

House com­mit­tee ad­vances an­oth­er PBM re­form bill that would ban spread pric­ing

Last year
Pharma
FDA+

Gilead stops last PhI­II of CD47 drug, cit­ing FDA hold, high­er risk of death in treat­ment arm

Last year
R&D

Lil­ly CEO rais­es con­cerns about No­vo-Catal­ent buy, call­ing the No­vo Nordisk deal ‘un­usu­al’

Last year
Deals
Manufacturing

Af­ter sweep of deals in 2023, Gilead to fo­cus on 'late re­search, ear­ly de­vel­op­men­t' pipeline

Last year
Deals

Jaz­z's KRAS deal with Redx; Al­to Neu­ro­science up­sizes IPO

Last year
News Briefing

I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

Last year
Deals
China

De­nali touts more bio­mark­er da­ta with ac­cel­er­at­ed ap­proval in mind

Last year
R&D

Ex­clu­sive: Top neu­ro­sci­en­tist Asa Abe­liovich tar­gets ALS, schiz­o­phre­nia with new start­up Leal af­ter $1B Lil­ly buy­out

Last year
Startups

As obe­si­ty mar­ket heats up, Am­gen leaves clues on Mar­i­Tide’s path for­ward

Last year
Pharma

Ex­clu­sive: Ver­tex founder Joshua Boger joins tiny Boston biotech as chair, ahead of mid-stage read­out for de­men­tia ...

Last year
People

Ex­clu­sive: With an eye to­ward ex­pan­sion, an AI com­pa­ny that sup­ports CD­MOs com­pletes $20M Se­ries C raise

Last year
Financing
Manufacturing

A new VC fund emerges with $310M to cre­ate in­de­pen­dent, com­mer­cial biotechs

Last year
Financing
Startups

Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Last year
Deals
Pharma

Gilead won't ac­quire check­point on­col­o­gy biotech Tizona

Last year
Deals
Pharma

Lil­ly to build man­u­fac­tur­ing ca­pac­i­ty at risk to pre­pare for next-gen oral obe­si­ty drug

Last year
Pharma
Manufacturing
First page Previous page 204205206207208209210 Next page Last page
A service from the Financial Times